학술논문
POSC5 Adjusting for Subsequent Therapies in the Tourmaline-MM1 Study Shows Clinically Meaningful Improvement in Overall Survival with Ixazomib in Combination with Lenalidomide and Dexamethasone (IXA+LEN+DEX) Compared to LEN+DEX
Document Type
Abstract
Author
Source
In Value in Health January 2022 25(1) Supplement:S33-S33
Subject
Language
ISSN
1098-3015